News

Pyxis Oncology to Showcase Innovations at November Conferences

Pyxis Oncology to Showcase Innovations at November Conferences

Pyxis Oncology to Showcase Innovations at November Conferences

Pyxis Oncology, Inc. (NASDAQ: PYXS), based in Boston, is a pioneering clinical-stage company dedicated to developing innovative therapies for some of the most challenging cancers. The company has recently announced its participation in notable investor conferences coming up this November 2025, marking an important opportunity for stakeholders and the public to learn more about their cutting-edge work.

Upcoming Conferences

Taking place in November, Pyxis Oncology will engage with investors through two key conferences:

Guggenheim 2nd Annual Healthcare Innovation Conference

The first event on the agenda is the Guggenheim Healthcare Innovation Conference, set for November 10, where the management team will participate in a fireside chat at 2:30 PM Eastern Time. This gathering underscores the company's commitment to transparency and shareholder engagement, providing insights into their strategic direction and advancements.

Stifel 2025 Healthcare Conference

Shortly after, on November 11 at 4:00 PM ET, Pyxis will also be featured at the Stifel 2025 Healthcare Conference, another significant event that promotes discussions around emerging healthcare technologies and investment opportunities. These conferences will allow Pyxis to highlight recent achievements and ongoing projects that could help reshape cancer treatment.

Access to Live Webcasts

For those who cannot attend the conferences in person, Pyxis Oncology will provide live webcasts of both fireside chats. These will be accessible through the Events & Presentations section on their Investor Relations webpage, ensuring that shareholders and interested parties can stay updated no matter their location.

About Pyxis Oncology, Inc.

Founded with the mission to innovate, Pyxis Oncology is at the forefront of biopharmaceutical development. One of its leading candidates is micvotabart pelidotin (MICVO), a groundbreaking antibody-drug conjugate designed specifically for targeting an important component of the tumor microenvironment. This innovative therapy focuses on a three-part action mechanism: directly killing tumor cells, eliciting a bystander effect, and promoting immunogenic cell death.

Currently undergoing Phase 1 clinical trials, MICVO is aimed at treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. This therapy is also being evaluated in combination with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), which represents a robust step in improving treatment outcomes.

Advancements in Cancer Therapy

Pyxis Oncology is not just an innovator but a leader ready to tackle the complex challenges of treating difficult cancers. Their work is vital in helping patients gain access to new therapeutic options, transforming lives with the hope of improved survival rates and quality of care. With an unwavering focus on new solutions, the company is poised to contribute significantly to advancements in oncology.

Contact Information

For more details about Pyxis' innovative approaches and ongoing developments, you can visit their official website or connect with their Investor Relations team:

Email: IR@pyxisoncology.com

Media Inquiries:
Cailyn McCutcheon,
Real Chemistry
cmccutcheon@realchemistry.com

Frequently Asked Questions

What is Pyxis Oncology focused on?

Pyxis Oncology is dedicated to developing innovative therapeutics to treat difficult-to-treat cancers, focusing on enhancing treatment effectiveness and patient outcomes.

When are the upcoming investor conferences?

The investor conferences will take place on November 10 and 11, 2025, featuring discussions about the company’s advancements and strategic direction.

How can I access the live webcasts?

Live webcasts of the fireside chats will be available on the Events & Presentations page of Pyxis Oncology’s Investor Relations website.

What is MICVO?

Micvotabart pelidotin (MICVO) is a first-in-class antibody-drug conjugate targeting the tumor microenvironment to improve cancer treatment outcomes.

How can I contact Pyxis Oncology for more information?

You can reach them via email at IR@pyxisoncology.com for investor inquiries or cmccutcheon@realchemistry.com for media inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Green Builder Media's Fresh Focus on Net Zero Homes

Updated Category News Views 2

There's a fresh breeze blowing through the building industry, and it's got "net zero" written all over it. Green Builder Media is rolling out a pile of new resources aimed at wrangling this beast of a trend. The focus? High-performance, all-electric homes. And they're not just whispering about it—they've got hard data and practical guidance to back up their claims. Net...

Continue Reading
Shareholder Deals Under Fire: PRTH, BWIN, CCC Scrutiny

Updated Category News Views 4

When Deals Leave Shareholders in the Lurch Here's the deal, folks—three companies are under scrutiny for transactions that might leave their shareholders dry while insiders make a pretty penny. Priority Technology Holdings, Inc. (NASDAQ:PRTH), Baldwin Group, Inc. (NASDAQ:BWIN), and CCC Intelligent Solutions Holdings Inc. (NASDAQ:CCC) are being probed by Halper Sadeh LLC...

Continue Reading
Procede Software Acquires RIMSS: Dealer Tech Shift?

Updated Category News Views 3

Procede's Big Play Seems like Procede Software is tossing the dice with its latest move. The software scene for dealership management is as cutthroat as a New York deli lineup, and now we've got Procede moving to scoop up RIMSS. This isn't just a back-office shuffle; it's a world-rocking maneuver that brings decades of dealer technology know-how into one basket. What's...

Continue Reading
QUA's EnviQ RF 30: A Game-Changer in Water Reuse

Updated Category News Views 2

Revolutionizing Water Treatment with Compact Solutions When you walk into a wastewater treatment facility, the last thing you expect is elegance. But elegance in efficiency is exactly what QUA is bringing to the table with their new EnviQ RF 30 compact membrane unit. This isn't your average pipe dream—it's a full-blown reality shaping the future of water reuse. A...

Continue Reading
DayOne Boosts NVIDIA DSX POD for Faster AI Era Advances

Updated Category News Views 2

AI Infrastructure Ramps Up with DayOne and NVIDIA Amid the hustle and bustle of today’s wild-tech landscape, DayOne's got its foot firmly on the pedal. This outfit’s throwing its weight behind NVIDIA's DSX POD reference design, revving up the standardized infrastructure game for AI. The word on the street from Singapore is that DayOne is coming in clutch with their...

Continue Reading
Unicycive's Stock Plunge: Fraud Suit and FDA Hurdles

Updated Category News Views 2

Unicycive's Tumultuous Journey Lately, it's been a rocky road for Unicycive Therapeutics, Inc., with their stock free-falling 39.1% in the span of a heartbeat on June 30, 2026. What sparked this nosedive? The FDA kicked back their revised New Drug Application for a kidney disease treatment yet again, spotlighting old manufacturing issues never nipped in the bud. Talk...

Continue Reading
AceMyNursingExams Debuts Versatile Nursing Prep Platform

Updated Category News Views 4

A Digital Lifeline for Nursing Students Nursing students are buried in responsibilities: lectures, clinical rotations, and sometimes even a job to fund the whole marathon. And just when they think they’ve got it handled, boom, a mountain of exams rises up in front of them. AceMyNursingExams gets this, rolling out an online exam prep platform to keep these future...

Continue Reading
Amynta's Southern States Deal: A Strategic Move?

Updated Category News Views 3

Digging Into Amynta's Latest Acquisition Alright, pull up a stool because Amynta Group just wrapped up a deal that could stir up the insurance pot a little. They snagged Southern States Underwriters, a specialty managing general underwriter focusing on commercial property and casualty insurance for the agribusiness sector. With this acquisition, Amynta doesn't just...

Continue Reading
FM's Bold $855M Resilience Credit: A Game Changer

Updated Category News Views 2

Breaking Down the US$855 Million Payout Just when you think you’ve got the insurance landscape figured out, FM spins the wheel with a US$855 million resilience credit, all thanks to its mutual structure and healthy results. Let’s unpack this hefty premium offset, shall we? A Second Year of Solid Savings This isn’t FM’s first rodeo. We're talking about a 10%...

Continue Reading
Brightstar Extends ONCE Contract for Spain Lottery Tech

Updated Category News Views 9

Brightstar's Steady Hand in the Lottery Fray Now here's a story that's got a touch of nostalgia coupled with forward-thinking ambition. Brightstar Lottery PLC, the big kahuna if you're talking about lottery tech, just snagged a multi-year contract extension with Spain's ONCE— the folks known for funding social programs with their lotteries. It’s not just any little...

Continue Reading

Top 5 Most Recently Viewed Articles

Fostering Collaboration in Healthcare Through Secure Solutions

Updated Category News Views 90

Enhancing Interoperability and Collaboration in Healthcare In an era where seamless integration is crucial, Secure Exchange Solutions (SES) emerges as a key player in the healthcare landscape. SES is part of Centauri Health Solutions, specializing in cloud-based clinical data exchange, and is dedicated to improving connectivity among healthcare providers. With its...

Continue Reading
Paris Baguette Celebrates Expansion with 200th U.S. Cafe Opening

Updated Category News Views 320

Paris Baguette Reaches a Milestone with 200th Cafe The celebrated bakery café brand, Paris Baguette, has officially opened its 200th cafe in North America, marking a tremendous achievement. With a strong commitment to serving communities, this milestone demonstrates the brand's ambition to provide freshly baked goods throughout the U.S. and Canada. Celebrating the 200th...

Continue Reading
Top Stocks for Strategic Diversification Amidst Trade Changes

Updated Category News Views 139

Navigating Economic Changes: A New Investment Landscape In recent times, shifts in economic policies have spurred conversations about potential revamps in the U.S. economy. The implementation of tariffs has emerged as a significant strategy aimed at revitalizing domestic manufacturing. This economic reset aims to strengthen national security while boosting local...

Continue Reading
Ascentage Pharma's Impressive Growth in 2025: A Review

Updated Category News Views 361

Overview of Ascentage Pharma's Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) recently announced its interim unaudited financial results for the first half of 2025. The report highlights significant growth, particularly in product sales, and provides exciting updates on ongoing clinical programs and commercial strategies. The company's...

Continue Reading
Parsons Corporation Secures Major $4B Defense Contract Award

Updated Category News Views 153

Parsons Corporation Wins $4 Billion Defense Contract Parsons Corporation has proudly announced that it has been awarded an indefinite-delivery, indefinite-quantity (IDIQ) multiple award task order contract (MATOC) by the Defense Threat Reduction Agency (DTRA). The lucrative contract has a ceiling value of $4 billion and is aimed at supporting Countering Weapons Of Mass...

Continue Reading